Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Millions of Americans use cannabis and would like to think the products they buy are safe. But regulation is state by state and full of holes. NPR's new series digs into the risks and solutions.
-
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.
-
RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, according to new filings with the Office of Government Ethics.
-
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
-
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including Ozempic, drugs for HIV, cancer and many others.
-
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.
-
IV fluids used in hospitals remain in short supply, after Hurricane Helene shut down a key North Carolina factory. The closure has hospitals scrambling to stretch supplies and prioritize care.
-
After Hurricane Helene flooded an IV fluid factory in North Carolina, the government and industry are trying to mitigate shortages.
-
Remnants of Hurricane Helene shut down a North Carolina factory that supplies critical IV fluids to hospitals across the country. There's no timeline for when production will resume at the facility.
-
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.